NCT07105254View on ClinicalTrials.gov

An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

May 15, 2026

Study Completion Date

June 15, 2026

Conditions
Non-segmental Vitiligo
Interventions
DRUG

Roflumilast topical 0.3% foam

Roflumilast 0.3% topical foam

Trial Locations (1)

75235

RECRUITING

Derm Texas, Dallas

Sponsors
All Listed Sponsors
collaborator

Arcutis Biotherapeutics, Inc.

INDUSTRY

lead

Derm Texas, PLLC

NETWORK